- Home
- BCC vs BBIO Comparison
BCC vs BBIO Comparison
Compare BCC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCC
- BBIO
- Stock Information
- Founded
- BCC 2004
- BBIO 2015
- Country
- BCC United States
- BBIO United States
- Employees
- BCC N/A
- BBIO N/A
- Industry
- BCC RETAIL: Building Materials
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BCC Consumer Discretionary
- BBIO Health Care
- Exchange
- BCC Nasdaq
- BBIO Nasdaq
- Market Cap
- BCC 4.9B
- BBIO 5.6B
- IPO Year
- BCC 2013
- BBIO 2019
- Fundamental
- Price
- BCC $127.95
- BBIO $33.79
- Analyst Decision
- BCC Buy
- BBIO Strong Buy
- Analyst Count
- BCC 5
- BBIO 13
- Target Price
- BCC $139.60
- BBIO $48.33
- AVG Volume (30 Days)
- BCC 387.5K
- BBIO 2.6M
- Earning Date
- BCC 02-18-2025
- BBIO 02-20-2025
- Dividend Yield
- BCC 4.55%
- BBIO N/A
- EPS Growth
- BCC N/A
- BBIO N/A
- EPS
- BCC 10.21
- BBIO N/A
- Revenue
- BCC $6,801,070,000.00
- BBIO $217,765,000.00
- Revenue This Year
- BCC N/A
- BBIO $2,309.33
- Revenue Next Year
- BCC $5.04
- BBIO N/A
- P/E Ratio
- BCC $12.53
- BBIO N/A
- Revenue Growth
- BCC N/A
- BBIO 2209.77
- 52 Week Low
- BCC $113.38
- BBIO $21.62
- 52 Week High
- BCC $155.42
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- BCC 52.87
- BBIO 68.27
- Support Level
- BCC $113.38
- BBIO $33.73
- Resistance Level
- BCC $122.00
- BBIO $36.24
- Average True Range (ATR)
- BCC 3.05
- BBIO 1.55
- MACD
- BCC 1.76
- BBIO 0.60
- Stochastic Oscillator
- BCC 86.29
- BBIO 72.81
About BCC Boise Cascade L.L.C.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two segments namely Wood Products and Building Materials Distribution. Wood Products segment manufactures EWP, consisting of laminated veneer lumber (LVL), I-joists, and laminated beams. The Building Materials Distribution segment is engaged in the wholesale of building materials. It distributes products such as plywood, OSB, and lumber items such as siding, doors, metal products, insulation, and roofing, EWP and others. The company generates a majority of its revenue from the Building Material Distribution segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.